🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. logo
Market Cap: Medium
Employees: Low

Gene Traffic Control platform

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. It utilizes its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Tags: biopharmaceutical, cancer treatment, chromatin regulatory system, gene traffic control, oncology, protein degrader, small molecule inhibitor

Website

About | Leadership | Contact | Contact | About

Symbol: FHTX

Recent Price: $4.61

Industry: Biotechnology

CEO: Mr. Adrian H. B. Gottschalk

Sector: Healthcare

Employees: 116

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 586 3100

Leadership

  • Steven Bellon, PHD, Chief Scientific Officer
  • Carlos Costa, Chief People Officer
  • Danette Daniels, PHD, VP, Protein Degrader Platform
  • Dan Dinu, MBA, VP, Information Technology
  • Michael Garcia-Webb, PHD, VP, Chief of Staff Research
  • Andrew Germain, PHD, VP, Legal
  • Adrian Gottschalk, President & CEO
  • Chong-Hui Gu, PHD, VP, CMC and QA
  • Karin Hellsvik, Chief of Staff to the CEO Vice President, Corporate Affairs and Investor Relations
  • Murphy Hentemann, PHD, VP, Program Leadership
  • Kristian Humer, MBA, Chief Financial Officer
  • Michael LaCascia, Chief Legal Officer
  • Marina Nelen, PhD, VP, Drug Discovery
  • Alfonso Quintás-Cardama, MD, Chief Medical Officer
  • Alena Reva, VP, Total Rewards & People Operations
  • Anna Rivkin, PHD, Chief Business Officer
  • Saurabh Sewak, PHD, VP, Corporate Development
  • Gromek Smolen, PHD, VP, Biology
  • Kevin Wilson, PHD, VP, Chemistry
  • José Baselga MD, PhD, In Memoriam
  • Scott Biller, PHD, Strategic Advisor, Agios Pharmaceuticals
  • Doug Cole, MD, Founder, Foghorn Therapeutics Managing Partner, Flagship Pioneering
  • Simba Gill, PhD, Former President & CEO, Evelo Biosciences
  • Cigall Kadoch, PhD, Scientific Advisor to the Board of Directors; Founder, Foghorn Therapeutics
  • Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
  • Tom Lynch, MD, President and Director, Fred Hutchinson Cancer Center
  • Michael Mendelsohn, MD, Chairman & Founder, Cardurion Pharmaceuticals
  • Lynne Parshall, Senior Strategic Advisor, Ionis Pharmaceuticals
  • Ian Smith, Chairman of the Board, Solid BioSciences
  • Gerald Crabtree, MD, Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute
  • Tony Kouzarides, PhD, FMedSci, FRS, Professor of Cancer Biology at the University of Cambridge Director of the Milner Therapeutics Institute and Deputy Director of the Gurdon Institute
  • Charles Sawyers, MD, Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; SAB Chair
  • David Schenkein, MD, General Partner, Co-leader, Google Ventures life science team Former CEO, Agios

Last updated: 2024-12-31